In a recently published report in JAMA Oncology, Shore et al evaluated the addition of enzalutamide to the current standard of care for patients with low- or intermediate-risk prostate cancer.1 According to the current National Comprehensive Cancer Network® (NCCN) guidelines, active surveillance (AS) is the current preferred recommendation for patients with very-low-risk and low-risk prostate cancer. For patients with intermediate-risk disease, AS is recommended, but not necessarily preferred over definitive therapy such as surgery or radiation.2 ...
Localized Prostate Cancer
Prostate Cancer Knowledge Hubs
Curated clinical content based on prostate cancer types, therapies, and technologies
The authors said that “PDEARGs are valuable prognostic predictors and potential therapeutic targets” for patients with ...
Smoking increased risk of urothelial carcinoma “more than expected” in patients with certain genetic risk factors.
Researchers developed a model to predict bladder cancer recurrence by combining microRNA with a pathological factor.